Powered by

-Medigene strengthens its patent portfolio with a US patent on a tagged TCR

Feb 05, 2018 - ENP Newswire

Planegg - Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology company focusing on the development of T cell immuno-therapies for the treatment of cancer, announces the grant of US patent 9,862,755 by the US Patent Office (USPTO) covering a high affinity T cell receptor with an epitope tag.

Applying an epitope tag to a high affinity T cell receptor potentially allows ex vivo and in vitro assessment of adoptively transferred T cell therapeutics. Potential applicat...